On the Brink of Change: How Academic Data and Machine Learning Can Revolutionize Alzheimer's Drug Development

In this white paper, you will:

• Hear about current industry challenges in Alzheimer’s drug development and glean insights as to why we must explore new clinical approaches
• Understand the importance of machine learning and predictive analytics for identifying non-diagnosed prodromal Alzheimer’s disease patients—and why we must tap into this unexplored general population to bring about real advancement
• Learn why innovative approaches to Alzheimer’s drug development are not only necessary, but how they will positively impact the future of Alzheimer’s disease for patients and the medical community alike